Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy – Business Wire

by

  1. Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Business Wire
  2. Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial STAT
  3. [Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints GlobeNewswire
  4. Even after primary miss, Sarepta to seek wider Elevidys approval FiercePharma
  5. Sarepta’s upcoming data on Duchenne gene therapy: What to know STAT
  6. View Full Coverage on Google News

Read original article here

Leave a Comment